Prof. Dr. med. Peter Fasching

Professur für Translationale Frauenheilkunde und Geburtshilfe

Molecular Subtyping of Invasive Breast Cancer Using a PAM50-Based Multigene Expression Test-Comparison with Molecular-Like Subtyping by Tumor Grade/Immunohistochemistry and Influence on Oncologist's Decision on Systemic Therapy in a Real-World Setting (2022) Erber R, Angeloni M, Stöhr R, Lux MP, Ulbrich-Gebauer D, Pelz E, Bankfalvi A, et al. Journal article Identification of Two Genetic Loci Associated with Leukopenia after Chemotherapy in Patients with Breast Cancer (2022) Fasching P, Liu D, Scully S, Ingle JN, Lyra PC, Rack B, Hein A, et al. Journal article Cost-effectiveness of pembrolizumab plus chemotherapy as first-line treatment in PD-L1-positive metastatic triple-negative breast cancer (2022) Huang M, Fasching P, Haiderali A, Pan W, Gray E, Zhou ZY, Hu P, et al. Journal article Corrigendum to “A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study”: [Annals of Oncology (2019), volume 30:1279-1288, (Annals of Oncology (2019) 30(1279-1288) (S0923753419312785)) (2022) Loibl S, Untch M, Burchardi N, Huober J, Sinn BV, Blohmer JU, Grischke EM, et al. Journal article, Erratum COST EFFECTIVENESS OF PEMBROLIZUMAB COMBINED WITH CHEMOTHERAPY VS. CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR METASTATIC TNBC THAT EXPRESSES PD-L1 IN THE UNITED STATES (2022) Huang M, Fasching P, Haiderali A, Pan W, Gray E, Zhou J, Hu PH, et al. Conference contribution Update Breast Cancer 2022 Part 2 - Advanced Stage Breast Cancer (2022) Müller V, Welslau M, Lüftner D, Schütz F, Stickeler E, Fasching P, Janni W, et al. Journal article, Review article Breast cancer risks associated with missense variants in breast cancer susceptibility genes (2022) Dorling L, Carvalho S, Allen J, Parsons MT, Fortuno C, Gonzalez-Neira A, Heijl SM, et al. Journal article Genetic Polymorphisms and Correlation with Treatment-Induced Cardiotoxicity and Prognosis in Patients with Breast Cancer (2022) Peddi PF, Fasching P, Liu D, Quinaux E, Robert NJ, Valero V, Crown J, et al. Journal article Smartphone-Based Colorimetric Analysis of Urine Test Strips for At-Home Prenatal Care (2022) Flaucher M, Nissen M, Jäger K, Titzmann A, Pontones C, Hübner H, Fasching P, et al. Journal article Ovarian function in young patients (pts) treated with postneoadjuvant palbociclib (PAL) and endocrine therapy (ET) for hormone receptor (HR)-positive, HER2-negative early breast cancer (BC): Explorative analysis in Penelope-B (2022) Furlanetto J, Marme F, Thode C, Nekljudova V, Liu Y, Jimenez MM, Reimer T, et al. Conference contribution